公开(公告)号：NO20014876L

公开(公告)日：2001-12-04

申请号：NO20014876

申请日：2001-10-08

Applicant: BASF AG

Inventor： HILLEN HEINZ ,  SCHMIDT MARTIN ,  MACK HELMUT ,  SEITZ WERNER ,  HAUPT ANDREAS ,  ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS

IPC: A61K38/00 ,  A61K38/55 ,  C12N9/99 ,  A61P1/04 ,  A61P1/18 ,  A61P5/14 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/02 ,  C07B43/00 ,  C07D401/12 ,  C07D409/12 ,  C07K5/06 ,  C07K5/062 ,  C07K5/065 ,  C07K5/068 ,  C07K5/072 ,  C07K5/078 ,  A61K38/05

Abstract: Peptide substances, their preparation and their use as complement inhibitors are described. These are in particular substances having a guanidine or amidine radical as a terminal group. In particular, inhibitors of the complement proteases C1s and C1r are described.

公开(公告)号：CZ247798A3

公开(公告)日：1999-03-17

申请号：CZ247798

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOFFKEN HANS WOLFGANG ,  SCHWEDEN JURGEN ,  RUBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：ZA971107B

公开(公告)日：1998-08-11

申请号：ZA971107

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOEFFKEN HANS WOLFGANG ,  SCHWEDEN JUERGEN ,  RUEBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  C07K ,  A61K ,  C07H

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：CO4600682A1

公开(公告)日：1998-05-08

申请号：CO97006960

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  BOLLSCHWEILE CLAUS ,  HANS WOLGANG ,  RUBSAMEN KLAUS ,  FRIEDRICH THOMAS ,  SCHWEDEN JURGEN ,  SCHMIDT MARTIN

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/36 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91

Abstract: LA PRESENTE INVENCION SE REFIERE A NUEVAS TROMBIN MUTEINAS SU PREPARACION Y UTILIZACION COMO ANTIDOTO PARA LOS INHIBIDORES DE LA TROMBINA.

公开(公告)号：AU1768497A

公开(公告)日：1997-08-28

申请号：AU1768497

申请日：1997-02-11

Applicant: BASF AG

Inventor： RADITSCH MARTIN ,  FRIEDRICH THOMAS ,  BOLLSCHWEILER CLAUS ,  SCHMIDT MARTIN ,  HOFFKEN HANS WOLFGANG ,  SCHWEDEN JURGEN ,  RUBSAMEN KLAUS

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/46 ,  A61P7/00 ,  A61P7/04 ,  C07K14/47 ,  C12N9/74 ,  C12N15/00 ,  C12N15/57 ,  C12R1/91 ,  A61K38/48

Abstract: PCT No. PCT/EP97/00612 Sec. 371 Date Aug. 4, 1998 Sec. 102(e) Date Aug. 4, 1998 PCT Filed Feb. 11, 1997 PCT Pub. No. WO97/29198 PCT Pub. Date Aug. 14, 1997The invention concerns thrombin muteins which have the following differences in their sequences as compared with natural thrombin: (a) the exchange of a Gly after Ala, the Gly being in the sequence environment Tyr-Gly-Phe and having position 558 in natural human thrombin (SEQ ID No. 14); (b) at least one exchange or deletion of the following radicals: (b1) His, located in the sequence environment Ala-His-Cys and having position 363 in natural human thrombin (SEQ ID No. 14); (b2) Asp, located in the sequence environment Arg-Asp-Ile and having position 419 in natural human thrombin (SEQ ID No. 14); (b3) Ser, located in the sequence environment Asp-Ser-Gly and having position 525 in natural human thrombin (SEQ ID No. 14). The invention further concerns the use of these muteins as antidotes.

公开(公告)号：TR200102913T2

公开(公告)日：2002-01-21

申请号：TR200102913

申请日：2000-03-28

Applicant: BASF AG

Inventor： HILLEN HEINZ ,  SCHMIDT MARTIN ,  MACK HELMUT ,  SEITZ WERNER ,  HAUPT ANDREAS ,  ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS

IPC: A61K38/00 ,  A61K38/55 ,  A61P1/04 ,  A61P1/18 ,  A61P5/14 ,  A61P7/02 ,  C12N9/99 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/02 ,  C07B43/00 ,  C07D401/12 ,  C07D409/12 ,  C07K5/06 ,  C07K5/062 ,  C07K5/065 ,  C07K5/068 ,  C07K5/072 ,  C07K5/078 ,  A61K38/05

Abstract: Peptide substances, their preparation and their use as complement inhibitors are described. These are in particular substances having a guanidine or amidine radical as a terminal group. In particular, inhibitors of the complement proteases C1s and C1r are described.

公开(公告)号：CA2369378A1

公开(公告)日：2000-10-19

申请号：CA2369378

申请日：2000-03-28

Applicant: BASF AG

Inventor： HILLEN HEINZ ,  SCHMIDT MARTIN ,  SEITZ WERNER ,  MACK HELMUT ,  ZECHEL JOHANN-CHRISTIAN ,  KLING ANDREAS ,  HAUPT ANDREAS

IPC: C12N9/99 ,  A61K38/00 ,  A61K38/55 ,  A61P1/04 ,  A61P1/18 ,  A61P5/14 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/02 ,  C07B43/00 ,  C07D401/12 ,  C07D409/12 ,  C07K5/06 ,  C07K5/062 ,  C07K5/065 ,  C07K5/068 ,  C07K5/072 ,  C07K5/078 ,  A61K38/05

Abstract: The invention relates to peptidic substances, to the production of said substances and to their use as complement inhibitors. In particular, the invention relates to substances with a guanidine or amidine radical as the terminal group, especially inhibitors of the complement proteases C1s and C1 r.

公开(公告)号：SK59896A3

公开(公告)日：1997-07-09

申请号：SK59896

申请日：1994-11-10

Applicant: BASF AG

Inventor： KROGER BURKHARD ,  SEULBERGER HARALD ,  MEYER THOMAS ,  SCHMIDT MARTIN ,  JACOB ELARD ,  OTTER RAINER ,  SUBKOWSKI THOMAS ,  HILLEN HEINZ

IPC: G01N33/573 ,  A01K67/027 ,  A61K31/70 ,  A61K35/12 ,  A61K38/00 ,  A61K38/43 ,  A61K38/48 ,  A61K39/395 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/04 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  C07H21/04 ,  C07K14/47 ,  C07K16/40 ,  C12N5/00 ,  C12N5/10 ,  C12N9/64 ,  C12N15/09 ,  C12N15/113 ,  C12N15/57 ,  C12R1/91 ,  C12N15/11

Abstract: PCT No. PCT/EP94/03706 Sec. 371 Date May 16, 1996 Sec. 102(e) Date May 16, 1996 PCT Filed Nov. 10, 1994 PCT Pub. No. WO95/14095 PCT Pub. Date May 26, 1995The invention relates to endothelin-converting enzymes containing the polypeptide sequence described in SEQ. ID. NO. 30 or SEQ. ID. NO. 36 or functional fragments thereof, genes which code for such enzymes, and processes for producing the said enzymes and the use thereof.

公开(公告)号：NO962023L

公开(公告)日：1996-07-16

申请号：NO962023

申请日：1996-05-15

Applicant: BASF AG

Inventor： KROGER BURKHARD ,  SEULBERGER HARALD ,  MEYER THOMAS ,  SCHMIDT MARTIN ,  JACOB ELARD ,  OTTER RAINER ,  SUBKOWSKI THOMAS ,  HILLEN HEINZ

IPC: G01N33/573 ,  A01K67/027 ,  A61K31/70 ,  A61K35/12 ,  A61K38/00 ,  A61K38/43 ,  A61K38/48 ,  A61K39/395 ,  A61K48/00 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/04 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  C07H21/04 ,  C07K14/47 ,  C07K16/40 ,  C12N5/00 ,  C12N5/10 ,  C12N9/64 ,  C12N15/09 ,  C12N15/113 ,  C12N15/57 ,  C12R1/91

Abstract: PCT No. PCT/EP94/03706 Sec. 371 Date May 16, 1996 Sec. 102(e) Date May 16, 1996 PCT Filed Nov. 10, 1994 PCT Pub. No. WO95/14095 PCT Pub. Date May 26, 1995The invention relates to endothelin-converting enzymes containing the polypeptide sequence described in SEQ. ID. NO. 30 or SEQ. ID. NO. 36 or functional fragments thereof, genes which code for such enzymes, and processes for producing the said enzymes and the use thereof.